Investigational Drug Information for AZD-4818
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for AZD-4818?
AZD-4818 is an investigational drug.
There have been 33 clinical trials for AZD-4818.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 15th 2021.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and National Cancer Institute (NCI).
There are eight US patents protecting this investigational drug and one hundred and twenty-nine international patents.
Summary for AZD-4818
| US Patents | 8 |
| International Patents | 129 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 3 (2021-09-15) |
| Vendors | 11 |
Recent Clinical Trials for AZD-4818
| Title | Sponsor | Phase |
|---|---|---|
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | AstraZeneca | Phase 3 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | Botswana Ministry of Health | Phase 3 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | Botswana Harvard AIDS Institute Partnership | Phase 3 |
Clinical Trial Summary for AZD-4818
Top disease conditions for AZD-4818
Top clinical trial sponsors for AZD-4818
US Patents for AZD-4818
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD-4818 | See Plans and Pricing | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | See Plans and Pricing |
| AZD-4818 | See Plans and Pricing | Entraining powder in an airflow | AstraZeneca AB (Sodertalje, SE) | See Plans and Pricing |
| AZD-4818 | See Plans and Pricing | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | Astrazeneca AB (Sodertalje, SE) | See Plans and Pricing |
| AZD-4818 | See Plans and Pricing | Inhalation device and method of dispensing medicament | AstraZeneca AB (Sodertalje, SE) | See Plans and Pricing |
| AZD-4818 | See Plans and Pricing | Breath activated inhaler | ASTRAZENECA AB (Sodertalje, SE) | See Plans and Pricing |
| AZD-4818 | See Plans and Pricing | Dispenser and method for entraining powder in an airflow | ASTRAZENECA AB (Sodertalje, SE) | See Plans and Pricing |
| AZD-4818 | See Plans and Pricing | Inhaler with indexing linked to movement of cover | ASTRAZENECA AB (SE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD-4818
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD-4818 | Argentina | AR099790 | 2034-03-18 | See Plans and Pricing |
| AZD-4818 | Australia | AU2015233195 | 2034-03-18 | See Plans and Pricing |
| AZD-4818 | Canada | CA2941807 | 2034-03-18 | See Plans and Pricing |
| AZD-4818 | Chile | CL2016002303 | 2034-03-18 | See Plans and Pricing |
| AZD-4818 | China | CN106103423 | 2034-03-18 | See Plans and Pricing |
| AZD-4818 | Costa Rica | CR20160479 | 2034-03-18 | See Plans and Pricing |
| AZD-4818 | Cyprus | CY1120509 | 2034-03-18 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
